Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Jacobio Invests $53 Million into Hebecell and its Stem Cell Based CAR-T Therapies

publication date: Sep 1, 2021

Jacobio, a Beijing-Shanghai Pharma, made a $53 million strategic investment in Boston-based Hebecell. Jacobio will collaborate with Hebecel to develop its next-gen natural killer cell therapies based on induced pluripotent stem cells (iPSC-NK). iPSC-NK uses natural killer cells that can be produced indefinitely from iPSC cells, without separating the cells from the patient's blood, a technology that has the potential to offer off-the-shelf CAR-T therapies. Dr. Yinxiang Wang, chairman and CEO of Jacobio, will become Chairman of Hebecell. More details....

Stock Symbol: (HK: 1167)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China